RESUMO
PURPOSE: Conventional therapy (calcium and activated vitamin D) does not restore calcium homeostasis in patients with chronic hypoparathyroidism (HypoPT) and is associated with renal complications and reduced quality of life (QoL). The aim of this study was to evaluate in a case-control, cross-sectional study, the rate of renal complications and QoL in two sex- and age-matched cohort of patients with differentiated thyroid cancer with (n = 89) and without (n = 89) chronic post-operative HypoPT (PoHypoPT) and their relationship with the biochemical control of the disease. METHODS: Serum and urinary parameters, renal ultrasound and QoL were assessed by SF-36 and WHO-5 questionnaires. RESULTS: Forty-three (48.3%) PoHypoPT patients reported symptoms of hypocalcemia. Twenty-six (29.2%) patients were at target for all 6 parameters, 46 (51.6%) for 5. The most frequently unmet targets were gender-specific 24-h urinary calcium (44.9%) and serum calcium (37.1%). Serum phosphate, magnesium and 25(OH)D were in the normal range in > 90% of patients. Renal calcifications were found in 26 (29.2%) patients, with no correlation with 24-h urinary calcium. eGFR did not differ between patients and controls. Conversely, patients had a significant higher rate of renal calcifications and a lower SF-36, but not WHO-5, scores. SF-36 scores did not differ between PoHypoPT patients who were, or not, hypocalcemic. CONCLUSIONS: Our study shows that the rate of renal calcifications was higher in patients with PoHypoPT than in those without. This finding, together with the reduced QoL and the presence of hypocalcemic symptoms in about half patients, underscores that the treatment of chronic HypoPT with conventional therapy is suboptimal.
Assuntos
Cálcio , Hipoparatireoidismo , Nefrolitíase , Complicações Pós-Operatórias , Qualidade de Vida , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia , Vitamina D/uso terapêutico , Cálcio/sangue , Cálcio/metabolismo , Cálcio/uso terapêutico , Cálcio/urina , Hormônios e Agentes Reguladores de Cálcio/metabolismo , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Feminino , Humanos , Hipocalcemia/sangue , Hipocalcemia/etiologia , Hipocalcemia/terapia , Hipocalcemia/urina , Hipoparatireoidismo/sangue , Hipoparatireoidismo/complicações , Hipoparatireoidismo/etiologia , Hipoparatireoidismo/psicologia , Masculino , Pessoa de Meia-Idade , Nefrolitíase/sangue , Nefrolitíase/etiologia , Nefrolitíase/psicologia , Nefrolitíase/terapia , Avaliação de Resultados em Cuidados de Saúde , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/psicologia , Complicações Pós-Operatórias/terapia , Inquéritos e Questionários , Neoplasias da Glândula Tireoide/patologia , Tireoidectomia/efeitos adversos , Tireoidectomia/métodosRESUMO
OBJECTIVE: This study was aimed to demonstrate the clinical benefits of rearranged during transfection (RET) genetic screening in patients with apparently sporadic medullary thyroid cancer (MTC) not only to identify the hereditary nature of the disease in the index case but also to discover family members harbouring the same germline mutations (i.e. gene carriers) who are unaware of their condition. CONTEXT: RET genetic screening allowed the identification of germline RET mutations in apparently sporadic MTC resulting in their re-classification as hereditary forms. PATIENTS AND MEASUREMENTS: RET genetic screening was performed in 729 apparently sporadic MTC patients by direct sequencing RET exons 5, 8, 10, 11 and 13-16. Clinical and biochemical evaluation of gene carriers was also performed. RESULTS: We discovered an unsuspected germline RET mutation in 47 of 729 (6·5%) apparently sporadic MTC who were re-classified as hereditary. We found 60 of 146 (41·1%) gene carriers, 35 of whom had biochemical or clinical evidence of MTC. Thirty gene carriers underwent total thyroidectomy and 27 of 30 (90%) were persistently cured after a mean follow-up of 6·0 years. As a further result of RET genetic screening, we observed a significantly higher prevalence of familial medullary thyroid cancer (FMTC) in our series with respect to the largest series of the International RET Consortium (P = 0·0002). CONCLUSIONS: RET genetic screening of patients with apparently sporadic MTC represents a major tool for the preclinical diagnosis and early treatment of unsuspected affected family members and allows the identification of a relevant percentage of hidden FMTC.
Assuntos
Testes Genéticos/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma/diagnóstico , Carcinoma/genética , Carcinoma Medular/congênito , Carcinoma Neuroendócrino , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasia Endócrina Múltipla Tipo 2a/genética , Síndromes Neoplásicas Hereditárias/diagnóstico , Síndromes Neoplásicas Hereditárias/genética , Reação em Cadeia da Polimerase , Neoplasias da Glândula Tireoide/diagnóstico , Neoplasias da Glândula Tireoide/genética , Adulto JovemRESUMO
Rearrangements of the RET proto-oncogene may occur in both naturally occurring and radiation-induced papillary thyroid carcinomas. Conflicting results on the frequency and type of RET/PTC rearrangements have been reported in relation to age, radiation exposure, and histological tumor variant. We designed the present study to evaluate in a single laboratory, using the same methodologies, the pattern of RET/PTC activation in thyroid tumors from different groups of patients (exposed or not exposed to radiation, children or adults, with benign or malignant tumors) in relationship to the above mentioned variables. We studied 154 patients with benign nodules (n = 65) or papillary thyroid cancer (n = 89). In the last group, 25 were Belarus children exposed to the post-Chernobyl radioactive fallout, 17 were Italian adults exposed to external radiotherapy for benign diseases, and 47 were Italian subjects (25 children and 22 adults) with no history of radiation exposure. Among patients with benign thyroid nodules, 21 were Belarus subjects (18 children and 3 adults) exposed to the post-Chernobyl radioactive fallout, 8 were Italian adults exposed to external radiation on the head and neck, and 36 were Italian adults with naturally occurring benign nodules. The overall frequency of RET/PTC rearrangements in papillary thyroid cancer was 55%. The highest frequency was found in post-Chernobyl children and was significantly higher (P = 0.02) than that found in Italian children not exposed to radiation, but not significantly higher than that found in adults exposed to external radiation. No difference of RET/PTC rearrangements was found between samples from irradiated (external x-ray) or not irradiated adult patients, as well as between children and adults with naturally occurring, not irradiated, thyroid cancer. When analyzing the type of RET/PTC rearrangement (RET/PTC1 or RET/PTC3), no major difference was apparent. In addition, eight cases with an unknown RET/PTC rearrangement and three cases with the concomitant expression of RET/PTC1 and RET/PTC3 were found. No significant correlation was observed between the frequency and/or the type of RET/PTC rearrangement and clinical-epidemiological features of the patients such as age at diagnosis, age at exposure, histological variant, gender and tumor-node-metastasis (TNM) categories. RET/PTC rearrangements were also found in 52.4% of post-Chernobyl benign nodules, in 37.5% of benign nodules exposed to external radiation and in 13.9% of naturally occurring nodules (P = 0.005, between benign post-Chernobyl nodules and naturally occurring nodules). The relative frequency of RET/PTC1 and RET/PTC3 in rearranged benign tumors showed no major difference. In conclusion, our results indicate that the presence of RET/PTC rearrangements in thyroid tumors is not restricted to the malignant phenotype, is not higher in radiation-induced tumors compared with those naturally occurring, is not different after exposure to radioiodine or external radiation, and is not dependent from young age. Other factors, probably influenced by ethnic or genetic background, may act independently from or in cooperation with radiation, to trigger the DNA damage leading to RET proto-oncogene activation.
Assuntos
Proteínas de Drosophila , Mutação , Proteínas de Fusão Oncogênica/genética , Proteínas Oncogênicas/genética , Proteínas Proto-Oncogênicas/genética , Liberação Nociva de Radioativos , Radioterapia/efeitos adversos , Receptores Proteína Tirosina Quinases/genética , Neoplasias da Glândula Tireoide/genética , Nódulo da Glândula Tireoide/genética , Fatores de Transcrição , Adolescente , Adulto , Idoso , Southern Blotting , Carcinoma Papilar/etiologia , Carcinoma Papilar/genética , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Coativadores de Receptor Nuclear , Reação em Cadeia da Polimerase , Proteínas Tirosina Quinases , Proto-Oncogene Mas , Proteínas Proto-Oncogênicas c-ret , RNA/análise , República de Belarus , Neoplasias da Glândula Tireoide/etiologia , UcrâniaRESUMO
Experiments were conducted to verify whether the neurohormone melatonin influences the membrane conductance of photoreceptors isolated from the frog retina. It has been found that 20 microM melatonin decreases membrane conductances both in the linear and non linear ranges by <0.4 nS. These actions are estimated to produce in dark adapted photoreceptors an increase of the response to a dim light induced change of the dark current of about 21%, i.e. from 1.3 to 1.62 mV/pA.
Assuntos
Melatonina/fisiologia , Potenciais da Membrana/fisiologia , Células Fotorreceptoras/fisiologia , Animais , AnurosRESUMO
This article reports the results of a study conducted from 1989 to 1995 of 423 hydroxyapatite-coated implants used for immediate tooth replacement after extraction in 353 patients with an age range from 15 to 68 years. The implants replaced teeth that were extracted because of periodontal disease, root fractures, and endodontic problems. Bone defects relative to the implant were treated with bone regeneration procedures using polytetrafluoroethylene (PTFE) membranes and resorbable collagen membranes with and without augmentation material (hydroxyapatite--188 cases, demineralized freeze-dried bone allograft--208 cases, and 27 cases without augmentation material). Histologic evaluation confirmed viability of the regenerated bone. The length of implants ranged from 8 mm to 18 mm, and a total of 284 PTFE and 139 collagen membranes were used. During the 1-year follow-up, 1 implant was lost and an additional implant failed during the 7-year follow-up, with a final success rate of 99.53%.
Assuntos
Implantação Dentária Endóssea/métodos , Implantes Dentários , Adolescente , Adulto , Idoso , Durapatita , Feminino , Regeneração Tecidual Guiada Periodontal , Humanos , Masculino , Membranas Artificiais , Pessoa de Meia-Idade , Politetrafluoretileno , Estudos Retrospectivos , Fatores de Tempo , Resultado do TratamentoRESUMO
Germline and somatic RET oncogene mutations are found in 98% hereditary and 40% sporadic medullary thyroid carcinomas. Our aim was to analyse by in silico and in vitro assays the transforming activity of six rare RET mutations (T338I, V648I, M918V, A883T, S904F and M848T). Six known RET mutations were used as controls. The in silico analysis showed the highest score value (i.e. 65) for S904F, M848T, M918T and C634R, whereas L790F, G691S, T338I and V648I had 0 score. Intermediate score values were obtained by A883T (score=55), M918V, V804M and Y791F (score=15). The in vitro focus formation assay showed that cells transfected with S904F, M918T, M848T or C634R generated the largest number of focus formation units (FFU). Intermediate numbers of FFU were observed in cells transfected with M918V, V804M, Y791F or A883T, while cells transfected with L790F, G691S, T338I or V648I showed a number of FFU similar to control cells. A positive correlation between the in silico score and in vitro FFU was found (P=0.0005). Only cells transfected with M918T or C634R grew faster and generated higher number of colonies in soft agar than control cells. However, the cells that were transfected with V804M produced an intermediate number of colonies. In conclusion, two of the six rare RET mutations, S904F and M848T possessed a relatively high transforming activity but a low aggressiveness; the other four mutations T338I, V648I, M918V and A883T were low or non-transforming, and their ability to induce tumoural transformation might be related to particular genetic conditions.
Assuntos
Carcinoma Medular/genética , Proteínas Proto-Oncogênicas c-ret/genética , Neoplasias da Glândula Tireoide/genética , Células 3T3 , Adulto , Alelos , Animais , Ensaio de Unidades Formadoras de Colônias , DNA de Neoplasias/química , DNA de Neoplasias/genética , Feminino , Variação Genética , Mutação em Linhagem Germinativa/genética , Humanos , Masculino , Camundongos , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Polimorfismo Genético , Alinhamento de Sequência , Análise de Sequência de DNA , TransfecçãoRESUMO
Two main types of RET/PTC oncogene, named RET/PTC-1 and 3, occur in papillary thyroid carcinomas especially in those from Belarus children after the Chernobyl nuclear accident. Several variants of RET/PTC-3 have also been found, having different break points with respect to the classical RET/PTC-3. To our knowledge, no variant of RET/PTC-1 has been described up to now. We found a post-Chernobyl papillary thyroid carcinoma with an RET/PTC-1 rearrangement characterized by a transcript longer than expected. Sequence analysis of the PCR product obtained after RT-PCR revealed new fusion points between H4 and RET genes. The genomic sequence showed new breakpoints in both H4 intronic and in RET exonic regions. The RET gene breakpoint occurred within exon 11, at variance with the classical form of RET/PTC-1, in which it is in intron 11. As a consequence of this new fusion point, the transcript included 132 nucleotides of exon 11, coding for 44 amino acids of RET protein. Regarding the H4 gene, the classical breakpoint is in the first intron and the cDNA contains a fragment of 339 nucleotides. In our case the cDNA had a longer fragment of H4 involving a total of 1266 nucleotides. Sequencing of genomic DNA revealed a rearrangement breakpoint at position 886 of a new H4 intron located downstream of the 1266 coding region. Furthermore, as a consequence of the activation of a cryptic splicing site, 132 nucleotides of this intron were spliced between the H4 and RET genes. Sequence analysis of the new chimera showed that the original frames of H4 and RET were joint with the intronic sequence without disruption of the open reading frame (ORF). Moreover, the genomic DNA of this case showed transforming activity in the DNA-mediated transfection assay using NIH-3T3 cells. In conclusion, we describe here the first variant of RET/PTC-1 oncogene, which we have termed 'long'-PTC-1, characterized by new breakpoints of both genes involved in the rearrangement and having transforming activity. Similar to previously reported PTC-3 variants, long-PTC-1 has been found in a post-Chernobyl papillary thyroid carcinoma confirming that RET/PTC rearrangements other than the classical forms (RET/PTC-1 and -3) are specifically associated with radiation-induced papillary thyroid cancer.
Assuntos
Carcinoma Papilar/genética , Neoplasias Induzidas por Radiação/genética , Proteínas de Fusão Oncogênica/genética , Neoplasias da Glândula Tireoide/genética , Criança , Quebra Cromossômica , Humanos , Masculino , Proteínas de Neoplasias/genética , Proteínas Tirosina Quinases , Liberação Nociva de Radioativos , UcrâniaRESUMO
Activating point mutations of RET gene have been demonstrated to be causative of the familial form of medullary thyroid cancer (MTC), both isolated (FMTC) and associated to other endocrine neoplasia [multiple endocrine neoplasia (MEN) 2A and 2B]. In RET gene mutation carriers, who are prone to developing MTC, prophylactic thyroidectomy is recommended to obtain their definitive cure. The simultaneous excision of the central node compartment is mandatory when the stimulation pentagastrin test for serum calcitonin is positive. Although the minimally invasive video assisted thyroidectomy (MIVAT) is nowadays currently adopted in many centers, it has never been employed for the prophylactic thyroidectomy of RET gene mutation carriers. The fear of obtaining an incomplete lymphadenectomy of the central compartment was the main reason for this reluctance. Since RET gene mutation carriers have often normal thyroid volume and, if involved, small lymph nodes, they indeed represent the best candidates to this approach especially when considering that they are usually young and concerned about the cosmetic results and the period of hospitalization. The excellent results obtained by MIVAT in the last few years induced us to propose this procedure together with a central compartment lymphadenectomy to 2 RET gene mutation carriers recently found by genetic screening. As assessed by a negative pentagastrin stimulation test performed after 6 months from the MIVAT, they were definitively cured without any surgical complication with the exception of a transient hypoparathyroidism. They showed a great satisfaction for both the cosmetic results and the very short period of hospitalization, thus supporting the idea that MIVAT can be used in association with the central node dissection for the prophylactic treatment of RET mutation gene carriers whose thyroid volume is still normal.